NCT07766122Not yet recruitingPhase 4
Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU
Pilot Study Evaluating PSMA Positron Emission Tomography for Monitoring Clinically Significant Prostate Cancer After Focal HIFU Treatment
Source: ClinicalTrials.gov · Last updated 5 Nov 2026
Brief summary (registry, in English)
There would appear to be a strong interest in functional nuclear imaging for assessing the response to focal PaC treatment. Investigator team hypothesise that the diagnostic performance of PSMA PET is noninferior to that of MRI in detecting clinically significant recurrent PaC after treatment with HIFU. The main objective was to evaluate the diagnostic performance of PSMA PET compared with MRI with reference to the gold standard of prostate biopsy one year after HIFU.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 10 Aug 2026
- Start date
- Feb 2027
- Primary completion date
- Feb 2029
- Lead sponsor
- University Hospital, Toulouse
- Diseases
- Prostate cancer
- NCT number
- NCT07766122
- EU CT number
- 2026-525181-22-00
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 30
- From Feb 2027 to the primary completion date, Feb 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any condition that, in the judgement of the investigators, would interfere with the subject's ability to
- Hypersensitivity to the active substances or to any of the excipients
- Conditions contraindicating magnetic resonance imaging (MRI), such as the presence of internal metallic devices.
- Liver failure
Lab values
- Chronic kidney disease with an eGFR ≤ 60 mL/min
Other
- Evidence of extra-prostatic extension or invasion of the seminal vesicles.
- provide informed consent, comply with study instructions, expose the subject to increased risk, or interfere with the interpretation of study results.
- Patients deprived of their liberty or under legal protection (curatorship and guardianship, safeguard of justice)
Who the study is looking for
- Patient with prostate cancer
- Age ≥ 70 years (HAS 2023)
- Life expectancy \> 5 years
- Clinical stage Clinical stage T1c - T2a PSA \< 20 ng/ml Biopsy :ISUP 2 unilateral on a maximum of 2 contiguous sextants with or without ipsilateral or contralateral focus ISUP1 single focus or multiple foci if only one ISUP 2 focus on targeted biopsy
- Imaging Single lesion PIRADS 3 or 4 or 5 Volume of prostate gland \< 150 ml
- Enrolled in a social security scheme
- Signature of consent
Age in the registry: 70 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier Universitaire de Toulouse Coordinator of this site? Confirm its status | Toulouse | France | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.